This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Statistics and Research Methods  • Ocular/ Adnexal Tumors  • Enucleation  • Alert me on articles by topic

Tero Kivelä, MD, FEBO; Emma Kujala, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Kilic et al¹ reported in the October 2005 issue of the Archives that preenucleation radiotherapy (PER) improved long-term survival of patients with uveal melanoma.

In their prospective study, 167 Dutch patients with uveal melanoma received 8-Gy PER in 2 fractions 2 days before enucleation in 1978 and 1992 (to convert gray to rad, multiply by 100).¹ A historical control group of 108 patients was treated by enucleation only (EO) in 1971 to 1992. Mean follow-up was 9.50 years in the PER group and 9.25 years in the EO group. No significant differences were observed in sex, tumor location, largest tumor diameter, cell type, and extrascleral growth between the 2 groups.

Survival after 4 years of follow-up was better in the PER group.¹ The effect did not occur prior to 4 years of follow-up and it was more evident in the 15-year all-cause survival . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Reduced Melanoma-Related Mortality in Uveal Melanoma by Preenucleation Radiotherapy
Emine Kilic, Theo Stijnen, Paulus T. V. M. de Jong, Cornelia M. Mooy, Wilhelmina M. H. Eijkenboom, Peter J. Ringens, and Gre P. M. Luyten
Arch Ophthalmol. 2005;123(10):1363-1367.
ABSTRACT | FULL TEXT  

RELATED LETTER

Preenucleation Radiotherapy, Uveal Melanoma, and Competing Risks—Reply
Emine Kilic, Theo Stijnen, and Gre P. M. Luyten
Arch Ophthalmol. 2008;126(4):581-582.
EXTRACT | FULL TEXT